Please check your internet connection and try again.
# Lorazepam
## Overview
Lorazepam is a benzodiazepine with anxiolytic, sedative, hypnotic, amnestic, anticonvulsant, and muscle relaxant properties. It is primarily metabolized by glucuronidation and has an intermediate half-life.
## Primary Indications
* Anxiety disorders
* Insomnia
* Status epilepticus (acute seizure management)
* Preoperative sedation
## Adult Dosing
* **Anxiety:** 0.5 mg to 2 mg orally three times daily. Maximum: 10 mg daily.
* **Insomnia:** 2 mg to 4 mg orally at bedtime.
* **Status Epilepticus:** 2 mg to 4 mg intravenously or intramuscularly. May repeat after 5 to 10 minutes if necessary, not to exceed 8 mg in a 3-hour period.
* **Preoperative Sedation:** 2 mg to 4 mg intramuscularly 2 hours before surgery, or 2 mg to 4 mg intravenously immediately before induction.
## Pediatric Dosing
Dosing in pediatrics is highly variable and should be guided by specific indication, patient weight, and response.
* **Anxiety/Sedation:** Limited data for routine use. Oral doses of 0.02 mg/kg to 0.05 mg/kg per dose, not to exceed 0.1 mg/kg/day or adult doses, have been used.
* **Status Epilepticus:** 0.1 mg/kg intravenously, not to exceed 4 mg per dose. May be repeated every 5 to 10 minutes if needed.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution, may require dose reduction.
* **Renal Impairment:** No specific adjustment typically recommended, but monitor for accumulation.
* **Elderly:** Start with lower doses (e.g., 0.5 mg orally twice daily) and titrate cautiously due to increased sensitivity and risk of sedation and falls.
## Contraindications
* Known hypersensitivity to lorazepam or other benzodiazepines.
* Acute narrow-angle glaucoma.
* Severe respiratory insufficiency (unless for acute seizure management).
* Severe hepatic insufficiency (e.g., hepatic encephalopathy).
## Adverse Effects
Common: Sedation, dizziness, unsteadiness, weakness, disorientation.
Less common: Paradoxical excitation, anterograde amnesia, respiratory depression (especially with IV administration or in combination with other CNS depressants), hypotension.
## Key Drug Interactions
* **CNS Depressants (opioids, alcohol, other sedatives/hypnotics):** Increased risk of profound sedation, respiratory depression, coma, and death.
* **Valproic acid:** May increase lorazepam plasma concentrations and prolong its half-life. Consider reducing lorazepam dose.
* **Theophylline/Aminophylline:** May antagonize the sedative effects of benzodiazepines.
## Monitoring
* Level of consciousness and sedation.
* Respiratory rate and oxygen saturation (especially with IV administration).
* Signs of paradoxical reactions.
* Effectiveness for the intended indication.
* Potential for dependence and withdrawal symptoms with prolonged use.
## Clinical Pearls
* Intravenous administration should be slow (e.g., 2 mg/minute) to minimize respiratory depression and hypotension.
* Avoid intramuscular administration in patients with poor muscle mass or shock.
* Consider the risk of dependence and withdrawal with prolonged use or abrupt discontinuation. Tapering is recommended.
* Lorazepam has no active metabolites, which can be advantageous in patients with hepatic impairment compared to some other benzodiazepines.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information and current guidelines for complete and up-to-date information before making clinical decisions.*
